Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
By A. Palumbo, A. Chanan-Khan, K. Weisel, A. Nooka, T. Masszi, M. Beksaç, I. Špička, V. Hungria, M. Munder, M. Mateos and 9 more. New England Journal of Medicine, 2016
1,387 citations recorded by the source corpus.
Subfields: Hematology, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/4b6955b411cfca27b45ad1343fedbdf3587c213d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Oncology
Citations in the corpus
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “Bortezomib, carfilzomib, and ixazomib are proteasome inhibitors.81-83 Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.71,84-86 Panobinostat is a deacetylase inhibitor.73,87 Stage 1 All of the following: • Serum albumin ≥3.5 g/dL • Serum beta-2-microglobulin <3.5 mg/L •”
- The role of ubiquitination in tumorigenesis and targeted drug discovery (2020, background): “In addition, marizomib has the ability to penetrate the blood–brain barrier and induce apoptosis in glioma cells with low toxicity on normal cells.(372) Thus, it has been applied in newly diagnosed glioblastoma (NCT03345095).”
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019, methodology): “‖ Cytogenetic risk was based on fluorescence in situ hybridization or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (del17p, t[14;16], or t[4;14]).”